Bisphosphonates in phenytoin-induced bone disorder

Bone

Volumn 48, Issue 3, 2011, Pages 597-606

  Khanna, Suruchi ^a   Pillai, Krishna K ^a   Vohora, Divya ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

Alendronate; Bone demineralization; Homocysteine; Ibandronate; Phenytoin; Risedronate

Indexed keywords

ALENDRONIC ACID; CALCIKIND; CALCIUM; CIPCAL; COLECALCIFEROL; FOLIC ACID; HOMOCYSTEINE; HYDROGEN PEROXIDE; IBANDRONIC ACID; PHENYTOIN; RISEDRONIC ACID; UNCLASSIFIED DRUG;

AMINO ACID BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DEMINERALIZATION; BONE DENSITY; BONE DISEASE; BONE MASS; BONE TURNOVER; CONTROLLED STUDY; DRUG EFFICACY; FOLIC ACID BLOOD LEVEL; MALE; MOUSE; NONHUMAN; OSTEOLYSIS; TREATMENT DURATION;

ANIMALS; ANTIOXIDANTS; BIOLOGICAL MARKERS; BONE DENSITY; BONE DISEASES; BONE REMODELING; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROSHOCK; FEMUR; FOLIC ACID; HOMOCYSTEINE; HYDROGEN PEROXIDE; MALE; MICE; PHENYTOIN;

EID: 79751531729     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2010.10.172     Document Type: Article

References (67)

1. Kruse R. Osteopathies in antiepileptic long-term therapy (preliminary report). Monatsschr Kinderheilkd 1968, 116:378-381.
2. Christiansen C., Rodbro P., Lund M. Incidence of anticonvulsant osteomalacia and effect of vitamin D: controlled therapeutic trial. Br Med J 1973, 4:695-701.
3. Lee R.H., Lyles K.W., Emeric C.C. A review of the effect of anticonvulsant medications on bone mineral density and fracture risk. Am J Geriatr Pharmacother 2010, 8:34-46.
4. Khanna S., Pillai K.K., Vohora D. Insights into liaison between antiepileptic drugs and bone. Drug Discov Today 2009, 14:428-435.
5. Patsalos P.N., Froscher W., Pisani F., Van Rijn C.M. The importance of drug interactions in epilepsy therapy. Epilepsia 2002, 43:365-385.
6. Cherian A., Thomas S.V. Status epilepticus. Ann Indian Acad Neurol 2009, 12:140-153.
7. McNamara J.O. Pharmacotherapy of the epilepsies. Goodman and Gilman's manual of pharmacology and therapeutics 2008, 333-334. McGraw-Hill Medical, New York. L.S. Goodman, A. Gilman, L.L. Brunton, K.L. Parker (Eds.).
8. Alison M.P., Martha J.M. Epilepsy and bone health in adults. Epilepsy Beh 2004, 5(2):24-29.
9. Valimaki M.J., Tiihonen M., Laitinen K., Tahtela R., Karkkainen M., Lamberg-Allardt C., et al. Bone mineral density measured by dual-energy X-ray absorptiometry and novel markers of bone formation and resorption in patients on anti-epileptic drugs. J Bone Miner Res 1994, 9:631-637.
10. Lambrinoudaki I., Christodoulakos G., Botsis D. Bisphosphonates. Ann NY Acad Sc 2006, 1092:397-402.
11. Mauck K.F., Clarke B.L. Diagnosis, screening, prevention, and treatment of osteoporosis. Mayo Clin Proc 2006, 81(5):662-672.
12. Gallagher J.C., Sai A.J. Molecular biology of bone remodeling: implications for new therapeutic targets for osteoporosis. Maturitas 2010, 65:301-307.
13. Jarvis C.I., Morin A.K., Lynch A.M. Bisphosphonates for osteoporosis prevention and treatment. Clin Rev Bone Miner Metab 2005, 3(1):3-18.
14. Tamura T., Aiso K., Johnston K.E., Black L., Faught E. Homocysteine, folate, vitamin B-12 and vitamin B-6 in patients receiving antiepileptic drug monotherapy. Epilepsy Res 2000, 40:7-15.
15. Valsamis H.A., Arora S.K., Labban B., McFarlane S.I. Antiepileptic drugs and bone metabolism. Nutr Metab 2006, 3:36-47.
16. Heath V. Use of antiepileptic drugs implicated in fracture risk. Nat Rev Endocr 2010, 6:60.
17. Nissen-Meyer L.S.H., Svalheim S., Tauboll E., Reppe S., Lekva T., Solberg L.B., et al. Levetiracetam, phenytoin, and valproate act differently on rat bone mass, structure and metabolism. Epilepsia 2007, 48:1850-1860.
18. Kimball A.W., Burnett W.T., Doherty D.G. Chemical protection against ionizing radiation. I. Sampling methods for screening compounds in radiation protection studies with mice. Radiat Res 1957, 7:1-12.
19. Litchfield J.T., Wilcoxon F. A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 1949, 96:99-113.
20. Tenniswood M., Bird C.E., Clark A.F. Acid phosphatase: androgen dependent markers of rat prostate. Can J Biochem 1976, 54:350-357.
21. Lowry O.H., Rosebrough N.J., Farr A.B., Randall R.J. Protein measurement with folin-phenol reagent. J Biol Chem 1951, 193:265-275.
22. Stegemann H., Staldera K. Determination of hydroxyproline. Clin Chim Acta 1967, 18(2):267-273.
23. Koracevic D., Koracevic G., Djordjevic V., Andrejevic S., Cosic V. Method for the measurement of antioxidant activity in human fluids. J Clin Pathol 2001, 54:356-361.
24. Onodera K., Takahashi A., Wakabayashi H., Kamei J., Sakurada S. Effects of menatetrenone on the bone and serum levels of vitamin K2 (menaquinone derivatives) in osteopenia induced by phenytoin in growing rats. Nutrition 2003, 19:446-450.
25. Valimaki M.J., Tiihonen M., Laitinen K., Tahtela R., Karkkainen M., Lamberg-Allardt C., et al. Bone mineral density measured by dual-energy X-ray absorptiometry and novel markers of bone formation and resorption in patients on antiepileptic drugs. Bone Miner Res 1994, 9(5):631-637.
26. Moro-Alvarez M.J., Curiel M.D., Piedra C., Marinoso M.L., Carrascal M.T. Bone disease induced by phenytoin therapy: clinical and experimental study. Eur Neurol 2009, 62:219-230.
27. Kubota F., Kifune A., Shibata N., Akata T., Takeuchi K., Takahashi S., et al. Bone mineral density of epileptic patients on long-term antiepileptic drug therapy: a quantitative digital radiography study. Epilepsy Res 1999, 33:93-97.
28. Stephen L.J., McLellan A.R., Harrisson J.H., Shapiro D., Dominiczak M.H., Sills G.J., et al. Bone density and antiepileptic drug: a case-controlled study. Seizure 1999, 8:339-342.
29. Kulak C.A., Borba V.Z., Silvado C.E., Paola L., Seibel M.J., Bilezikian J.P., et al. Bone density and bone turnover markers in patients with epilepsy on chronic antiepileptic drug therapy. Arq Bras Endocrinol Metabol 2007, 51:466-471.
30. Black D.M., Cummings S.R., Karpf D.B., Cauley J.A., Thompson D.E., Nevitt M.C., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996, 348:1535-1541.
31. Hochberg M.C., Ross P.D., Black D., Cummings S.R., Genant H.K., Nevitt M.C., et al. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Arthritis Rheum 1999, 42:1246-1254.
32. Harris S.T., Watts N.B., Genant H.K., McKeever C.D., Hangartner T., Keller M., et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 1999, 282:1344-1352.
33. Chesnut C.H., Skag A., Christiansen C., Recker R., Stakkestad J.A., Hoiseth A., et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004, 19:1241-1249.
34. Reginster J.Y., Adami S., Lakatos P., Greenwald M., Stepan J.J., Silverman S.L., et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2year results from the MOBILE study. Ann Rheum Dis 2006, 65:654-661.
35. Silverman S.L., Watts N.B., Delmas P.D., Lange J.L., Lindsay R. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int 2007, 18:25-34.
36. Larsen E.R., Mosekilde L., Foldspang A. Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: a pragmatic population-based 3-year intervention study. J Bone Miner Res 2004, 19(3):370-378.
37. Jackson R.D., LaCroix A.Z., Gass M., Wallace R.B., Robbins J., Lewis C.E., et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006, 354(7):669-683.
38. Yoshiaki D. 5,5-diphenyl-2,4-imidazolidinedion induced osteoclastogenesis in codulture system of osteoblasts and bone marrow cells. Hokkaido J Dental Sci 2002;23(1):16-22.
39. Murakami H., Takahashi N., Sasaki T., Udagawa N., Tanaka S., Nakamura I., et al. A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone 1995, 17:137-144.
40. Jowsey J., Arnaud S.B., Hodgson S.F., Johnson K.A., Beabout J.W., Wahner H.W. The frequency of bone abnormality in patients on anticonvulsant therapy. Electroencephalogr Clin Neurophysiol 1978, 45:341-347.
41. Vasikaran S.D., Glendenning P., Morris H.A. The role of biochemical markers of bone turnover in osteoporosis management in clinical practice. Clin Biochem Rev 2006, 27:119-121.
42. Christenson R.H. Biochemical markers of bone metabolism: an overview. Clin Biochem 1997, 30:573-593.
43. Im G.-I.I., Qureshi S.A., Kenney J., Rubash H.E., Shanbhag A.S. Osteoblast proliferation and maturation by bisphosphonates. Biomater 2004, 25:4105-4115.
44. Giuliani N., Girasole G., Pedrazzoni M., Passeri G., Gatti C., Passeri M. Alendronate stimulates b-FGF production and mineralized nodule formation in human osteoblastic cells and osteoblastogenesis in human bone marrow cultures. J Bone Miner Res 1995, 10(1):S171.
45. Mundy G., Garrett R., Harris S., Chan J., Chen D., Rossini G., et al. Stimulation of bone formation in vitro and in rodents by statins. Science 1999, 286:1946-1949.
46. Plotkin L.I., Weinstein R.S., Parfitt A.M., Roberson P.K., Manolagas S.C., Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 1999, 104(10):1363-1374.
47. Delmas P.D. Biochemical markers of bone turnover. I: theoretical considerations and clinical use in osteoporosis. Am J Med 1993, 95:11-6S.
48. Kleerekoper M., Edelson G.W. Biochemical studies in the evaluation and management of osteoporosis: current status and future prospects. Endocrin Pract 1996, 2:13-19.
49. Viguet-Carrin S., Garnero P., Delmas P.D. The role of collagen in bone strength. Osteoporos Int 2006, 17:319-336.
50. Nishikawa M., Akatsu T., Katayama Y., Yasutomo Y., Kado S., Kugai N., et al. Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures. Bone 1996, 18(1):9-14.
51. Selhub J. Homocysteine metabolism. Ann Rev Nutr 1999, 19:217-246.
52. Tamura T., Aiso K., Johnston K.E., Black L., Faught E. Homocysteine, folate, vitamin B-12 and vitamin B-6 in patients receiving antiepileptic drug monotherapy. Epilepsy Res 2000, 40:7-15.
53. Hoffbrand A.V., Necheles T.F. Mechanism of folate deficiency in patients receiving phenytoin. Lancet 1968, 292(7567):528-530.
54. Lewis D.P., Van Dyke D.C., Willhite L.A., Stumbo P.J., Berg M.J. Phenytoin-folic acid interaction. Ann Pharmacother 1995, 29(7-8):726-735.
55. Carl G.F., Hudson F.Z., McGuire B.S. Phenytoin-induced depletion of folate in rats originates in liver and involves a mechanism that does not discriminate folate form. J Nutr 1997, 127(11):2231-2238.
56. Carl G.F., Smith D.B. The effect of chronic phenytoin treatment on tissue folate concentrations and on the activities of the methyl synthetic enzymes in the rat. J Nutr 1983, 113:2368-2374.
57. Kapoor P., Ansari M.N., Bhandari U. Modulatory effect of curcumin on methionine-induced hyperlipidemia and hyperhomocysteinemia in albino rats. Ind J Exp Biol 2008, 46:534-540.
58. Van Meurs J.B., Pluijm S.M. Homocysteine level and the risk of osteoporotic fracture. N Engl J Med 2004, 350:2033-2041.
59. Elliott J.O., Jacobson M.P., Haneef Z. Homocysteine and bone loss in epilepsy. Seizure 2007, 16:22-34.
60. Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia. J Clin Invest 1996, 98:5-7.
61. Garrett I.R., Boyce B.F., Oreffo R.O.C., Bonewald L., Poser J., Mundy G.R. Oxygen derived free radicals stimulate osteoclastic bone resorption in rodent bone in vitro and in vivo. J Clin Invest 1990, 85:632-639.
62. Suda N., Morita I., Kuroda T., Murota S. Participation of oxidative stress in the process of osteoclast differentiation. Biochim Biophys Acta 1993, 1157:318-323.
63. Raisanen S., Alatalo S., Ylipahkala H., Halleen J., Cassady A., Hume D., et al. Macrophages overexpressing tartrate-resistant acid phosphatase show altered profile of free radical production and enhanced capacity of bacterial killing. Biochem Biophy Res Comm 2005, 331:120-126.
64. Luckey M.M., Gilchrist N., Bone H.G., Davie M.W., de Villiers T.J., Wu M., et al. Therapeutic equivalence of alendronate 35 milligrams once weekly and 5 milligrams daily in the prevention of postmenopausal osteoporosis. Obstet Gynecol 2003, 101:711-721.
65. Adami S. Bisphosphonate antifracture efficacy. Bone 2007, 41:S8-S15.
66. Reginster J., Minne H.W., Sorensen O.H., Hooper M., Roux C., Brandi M.L., et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000, 11:83-91.
67. Drezner M.K. Treatment of anticonvulsant drug-induced bone disease. Epilepsy Behav 2004, 5:S41-S47.